A practical reference on freeze-thaw: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-04. Anything still debated is marked as such rather than presented as settled.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilised powder | visual inspection of solid |
| Solubility | Freely soluble in water, pH dependent | buffer choice affects clarity |
| Typical storage | -20 °C, desiccated, protected from light | solution form kept at 2-8 °C |
| Primary purity method | RP-HPLC with UV detection, 214-220 nm | reported as area percent |
| Identity confirmation | LC-ESI-MS, approximately 4114 Da | compared with theoretical mass |
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
The alcohol 3 was then converted into the acetate 4 via acetic anhydride-pyridine at room temperature with an overall yield of 90%. The acetate was then converted to the hydroxymethyl derivative 5 in three steps (1. TFA/room temperature; 2. ClCO2Et/Et3N-CH2Cl2/room temperature; 3. NaBH4/CH3OH-CH2Cl2/0 °C. Mesylation of 5 (MsCl/CH3OH-Et3N-CH2Cl2/0 °C), followed by lithium chloride treatment in DMF and hydrolysis (NaOCH3/CH3OH-CH2Cl2/room temperature) give the chloride 6 at a 95% overall yield. Adding phenyllithium slowly to a mixture of 6 and chloromethyl benzyl ether in excess in THF at 78 °C gave the benzylgliotoxin adduct 7 at 45% yield. Next, boron trichloride treatment of 7 in in methylene chloride at 0 °C yielded the gliotoxin anisaldehyde adduct 8 at 50% yield. Finally, acid oxidation of 8 followed by perchloric acid treatment in methylene chloride at room temperature yielded d,l-gliotoxin in a 65% yield. Spectroscopic analysis (NMR, ir, uv, MS) and TLC comparison showed that the synthetic substance was identical to natural gliotoxin. At least a couple of alternative syntheses are known to be reported in the pendant literature.
She at first taught them to rub patients' heads, to "lay [their] hands where the belief is to rub it out forever"; Kennedy would manipulate each student's head and solar plexus before class in preparation. The head rubbing was abandoned when the women complained about having to take their hair down, and the stomach rubbing held no appeal for them either. Eventually Eddy told them to ignore that part of the manuscript, and from then on Christian Science healing did not involve touching patients. In 1879 Eddy sued two of the students (unsuccessfully) for royalties from their practices. They testified that she had claimed she no longer needed to eat and had seen the dead raised. Eddy told the judge she meant she had "seen the dead in understanding raised".
In January 2023, Foreign Minister Mauro Vieira announced Brazil's return to the Community of Latin American and Caribbean States (CELAC). During the 7th CELAC summit, Lula expressed support for a modernization of the South American customs union Mercosur and the creation of a common unit of account between Argentina and Brazil which other South American nations could also join to boost regional integration and skip US dollar dominance. On 25 January, during a trip to Uruguay, Lula called for the European Union-Mercosur trade deal to be sealed and a China-Mercosur trade agreement to be explored. Lula and Uruguayan president Luis Lacalle Pou held talks over infrastructure projects to be developed in Uruguay, including a joint Uruguayan-Brazilian administration of the Rivera International Airport. In March 2023, Uruguayan and Brazilian top officials jointly detailed the said infrastructure projects in Brasília. Brazil also invited Paraguay and Uruguay to join the works of the G20 ahead of the 2024 G20 Brazil summit, as Brazilian rotating presidency in the group was to begin on 1 December 2023. In December 2024, during a summit in Montevideo attended by Lula and Ursula von der Leyen, Mercosur struck a definitive free trade agreement with the European Union representing nearly a quarter of the global gross domestic product (GDP).
== Function and location == The OXTR protein belongs to the G protein-coupled receptor (GPCR) family, specifically Gq, and acts as a receptor for oxytocin. Its activity is mediated by G proteins that activate several different second messenger systems. Oxytocin receptors are expressed by the myoepithelial cells of the mammary gland, and in both the myometrium and endometrium of the uterus at the end of pregnancy. The oxytocin receptor system plays an important role as an inducer of uterine contractions during parturition and of milk ejection. OXTR is also associated with the central nervous system. The gene is believed to play a major role in social, cognitive, and emotional behavior. A decrease in OXTR expression by methylation of the OXTR gene is associated with callous and unemotional traits in adolescence, rigid thinking in anorexia nervosa, problems with facial and emotional recognition, and difficulties in the affect regulation. A reduction in this gene is believed to lead to prenatal stress, postnatal depression, and social anxiety. Studies on OXTR methylation—which downregulates oxytocin mechanisms—suggest this process is associated with increased gray matter density in the amygdala, implicating OXTR regulation in stress and parasympathetic regulation. Social isolation has been found to decrease oxytocin receptor levels in rodents, whereas levels of oxytocin were unchanged.
According to the North American Mycological Association (NAMA) however, "[i]n humans, no reliably documented cases of death from toxins in these mushrooms [mushrooms that contain isoxazole derivatives] in the past 100 years, though there is one case where a camper froze to death while in the comatose state".
Sources: en.wikipedia.org
DNA usually occurs as linear chromosomes in eukaryotes, and circular chromosomes in prokaryotes. The set of chromosomes in a cell makes up its genome; the human genome has approximately 3 billion base pairs of DNA arranged into 46 chromosomes. The information carried by DNA is held in the sequence of pieces of DNA called genes. Transmission of genetic information in genes is achieved via complementary base pairing. For example, in transcription, when a cell uses the information in a gene, the DNA sequence is copied into a complementary RNA sequence through the attraction between the DNA and the correct RNA nucleotides. Usually, this RNA copy is then used to make a matching protein sequence in a process called translation, which depends on the same interaction between RNA nucleotides. In an alternative fashion, a cell may copy its genetic information in a process called DNA replication. The details of these functions are covered in other articles; here the focus is on the interactions between DNA and other molecules that mediate the function of the genome.
Biotechnology has contributed to the discovery and manufacturing of traditional small molecule pharmaceutical drugs as well as drugs that are the product of biotechnology – biopharmaceutics. Modern biotechnology can be used to manufacture existing medicines relatively easily and cheaply. The first genetically engineered products were medicines designed to treat human diseases. To cite one example, in 1978 Genentech developed synthetic humanized insulin by joining its gene with a plasmid vector inserted into the bacterium Escherichia coli. Insulin, widely used for the treatment of diabetes, was previously extracted from the pancreas of abattoir animals (cattle or pigs). The genetically engineered bacteria are able to produce large quantities of synthetic human insulin at relatively low cost. Biotechnology has also enabled emerging therapeutics like gene therapy. The application of biotechnology to basic science (for example through the Human Genome Project) has also dramatically improved our understanding of biology and as our scientific knowledge of normal and disease biology has increased, our ability to develop new medicines to treat previously untreatable diseases has increased as well. Genetic testing allows the genetic diagnosis of vulnerabilities to inherited diseases, and can also be used to determine a child's parentage (genetic mother and father) or in general a person's ancestry.
== Partial list of peptide hormones in humans == Adrenocorticotropic hormone (ACTH) Adropin Amylin Angiotensin Atrial natriuretic peptide (ANP) Calcitonin Cholecystokinin (CCK) Gastrin Ghrelin Glucagon Glucose-dependent insulinotropic polypeptide (GIP) Glucagon-like peptide-1 (GLP-1) Growth hormone Follicle-stimulating hormone (FSH) Human chorionic gonadotropin (hCG) Insulin Leptin Luteinizing hormone (LH) Melanocyte-stimulating hormone (MSH) Orexin/Hypocretin Oxytocin Parathyroid hormone (PTH) Prolactin Renin Somatostatin Thyroid-stimulating hormone (TSH) Thyrotropin-releasing hormone (TRH) Vasopressin, also called arginine vasopressin (AVP) or anti-diuretic hormone (ADH) Vasoactive intestinal peptide (VIP) Somatotropin (GH1) Gonadotropin Releasing Hormone 1 (GNRH1) Gonadotropin Releasing Hormone 2 (GNRH2) Growth Hormone Releasing Hormone (GHRH) Parathyroid Hormone Like Hormone (PTHLH) Corticotropin Releasing Hormone (CRH) Anti-Müllerian Hormone (AMH) Chorionic Somatomammotropin Hormone 1 (CSH1) Chorionic Somatomammotropin Hormone 2 (CSH2) Pro-Melanin Concentrating Hormone (PMCH) Resistin (RETN)
EAR US Estimated Average Requirements. RDA US Recommended Dietary Allowances; higher for adults than for children, and may be even higher for women who are pregnant or lactating. AI US and EFSA Adequate Intake; AIs established when there is not sufficient information to set EARs and RDAs. PRI Population Reference Intake is European Union equivalent of RDA; higher for adults than for children, and may be even higher for women who are pregnant or lactating. For Thiamin and Niacin the PRIs are expressed as amounts per MJ of calories consumed. MJ = megajoule = 239 food calories. UL or Upper Limit Tolerable upper intake levels. ND ULs have not been determined. NE EARs have not been established.
Sources: en.wikipedia.org
Reverse-phase high-performance liquid chromatography with ultraviolet detection is the usual choice, with results reported as area percent. Complementary methods such as size-exclusion chromatography and mass spectrometry are needed because a single separation cannot resolve every impurity class. Purity figures are therefore method dependent and should always be read alongside the technique used.
Oxidation mainly affects methionine residues and is promoted by dissolved oxygen, trace transition metals, and prolonged exposure to light. Buffer choice and the presence of antioxidants in a formulation can alter the rate appreciably. Because the products differ in mass by only a few units, mass spectrometry is often required to detect them.
Published data on long-term ambient stability are limited, so the question remains open rather than settled. Short excursions during transport are common in practice, and many suppliers use insulated packaging with cold packs. Where stability data are absent, cold-chain handling with temperature logging is the safer approach.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.